» Articles » PMID: 22846385

Factors Associated with Being Lost to Follow-up Before Completing Tuberculosis Treatment: Analysis of Surveillance Data

Overview
Date 2012 Aug 1
PMID 22846385
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Completion of treatment is key to tuberculosis control. Using national surveillance data we assessed factors associated with tuberculosis patients being lost to follow-up before completing treatment ('lost'). Patients reported in England, Wales and Northern Ireland between 2001 and 2007 who were lost 12 months after beginning treatment were compared to those who completed, or were still on treatment, using univariable and multivariable logistic regression. Of 41 120 patients, men [adjusted odds ratio (aOR) 1·29; 95% confidence interval (CI) 1·23-1·35], 15- to 44-year-olds (P<0·001), and patients with pulmonary sputum smear-positive disease (aOR 1·25, 95% CI 1·12-1·45) were at higher risk of being lost. Those recently arrived in the UK were also at increased risk, particularly those of the White ethnic group (aOR 6·39, 95% CI 4·46-9·14). Finally, lost patients had a higher risk of drug resistance (aOR 1·41, 95% CI 1·17-1·69). Patients at risk of being lost require enhanced case management and novel case retention methods are needed to prevent this group contributing towards onward transmission.

Citing Articles

Effect of Cost-Exemption Policy on Treatment Interruption in Patients With Newly Diagnosed Pulmonary Tuberculosis in South Korea.

Lee S, Lee J, Ji H, Lee J, Park S, Han C Int J Health Policy Manag. 2024; 13:8262.

PMID: 39099483 PMC: 11365073. DOI: 10.34172/ijhpm.8262.


Digital technologies and loss to follow-up for TB patients.

Sekandi J, Tucker E, Zalwango S, Buregyeya E Int J Tuberc Lung Dis. 2021; 25(10):871-872.

PMID: 34615588 PMC: 10284633. DOI: 10.5588/ijtld.21.0234.


Predictors of mortality and loss to follow-up among drug resistant tuberculosis patients in Oromia Hospitals, Ethiopia: A retrospective follow-up study.

Woldeyohannes D, Tekalegn Y, Sahiledengle B, Assefa T, Aman R, Hailemariam Z PLoS One. 2021; 16(5):e0250804.

PMID: 33956812 PMC: 8101723. DOI: 10.1371/journal.pone.0250804.


Tuberculosis treatment outcomes of notified cases: trends and determinants of potential unfavourable outcome, France, 2008 to 2014.

Guthmann J, Leon L, Antoine D, Levy-Bruhl D Euro Surveill. 2020; 25(4).

PMID: 32019670 PMC: 7001242. DOI: 10.2807/1560-7917.ES.2020.25.4.1900191.


Trends in tuberculosis notification and mortality and factors associated with treatment outcomes in Serbia, 2005 to 2015.

Stosic M, Sipetic Grujicic S, Grgurevic A, Kuruc V, Ristic L, Antonijevic G Euro Surveill. 2020; 25(1).

PMID: 31937395 PMC: 6961260. DOI: 10.2807/1560-7917.ES.2020.25.1.1900322.


References
1.
Antoine D, French C, Jones J, Watson J . Tuberculosis treatment outcome monitoring in England, Wales and Northern Ireland for cases reported in 2001. J Epidemiol Community Health. 2007; 61(4):302-7. PMC: 2652938. DOI: 10.1136/jech.2005.044404. View

2.
Dahle U, Sandven P, Heldal E, Mannsaaker T, Caugant D . Deciphering an outbreak of drug-resistant Mycobacterium tuberculosis. J Clin Microbiol. 2003; 41(1):67-72. PMC: 149644. DOI: 10.1128/JCM.41.1.67-72.2003. View

3.
Kruijshaar M, Abubakar I . Increase in extrapulmonary tuberculosis in England and Wales 1999-2006. Thorax. 2009; 64(12):1090-5. DOI: 10.1136/thx.2009.118133. View

4.
Story A, Murad S, Roberts W, Verheyen M, Hayward A . Tuberculosis in London: the importance of homelessness, problem drug use and prison. Thorax. 2007; 62(8):667-71. PMC: 2117290. DOI: 10.1136/thx.2006.065409. View

5.
Kulane A, Ahlberg B, Berggren I . "It is more than the issue of taking tablets": the interplay between migration policies and TB control in Sweden. Health Policy. 2010; 97(1):26-31. DOI: 10.1016/j.healthpol.2010.02.014. View